Recent Investment Analysts’ Ratings Changes for Bio-Techne (TECH)

Bio-Techne (NASDAQ: TECH) has recently received a number of price target changes and ratings updates:

• 8/25/2026 – Bio-Techne was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/25/2026 – Bio-Techne was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/19/2026 – Bio-Techne had its “hold” rating reaffirmed by Benchmark Co..
• 8/13/2026 – Bio-Techne was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $73.00 price target on the stock, up from $62.00.
• 8/4/2026 – Bio-Techne had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 7/9/2026 – Bio-Techne was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $73.00 price target on the stock, up from $62.00.
• 7/6/2026 – Bio-Techne was downgraded by Evercore Inc from “strong-buy” to “hold”.
• 6/30/2026 – Bio-Techne was downgraded by Benchmark Co. from “buy” to “hold”.
• 6/29/2026 – Bio-Techne was downgraded by TD Cowen from “buy” to “hold”. They now have a $73.00 price target on the stock, up from $65.00.

Bio-Techne Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 4th. Shareholders of record on Monday, August 24th will be issued a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a yield of 3.6%. The ex-dividend date is Monday, August 24th. This is an increase from Bio-Techne’s previous quarterly dividend of $0.08. Bio-Techne’s payout ratio is 27.83%.

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.